Research Article
Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients
@INPROCEEDINGS{10.4108/eai.13-11-2018.2283636, author={Gestina Aliska and Erlina Rustam and Elly Usman and Ivan Mahendra Raditya}, title={Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients}, proceedings={Proceedings of the 1st EAI International Conference on Medical And Health Research, ICoMHER November 13-14th 2018, Padang, West Sumatera, Indonesia}, publisher={EAI}, proceedings_a={ICOMHER}, year={2019}, month={5}, keywords={anticoagulants bleeding warfarin}, doi={10.4108/eai.13-11-2018.2283636} }- Gestina Aliska
Erlina Rustam
Elly Usman
Ivan Mahendra Raditya
Year: 2019
Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients
ICOMHER
EAI
DOI: 10.4108/eai.13-11-2018.2283636
Abstract
Oral anticoagulant (OAC) is used for thromboembolic prevention in atrial fibrillation (AF) patients. This study aim to observe the use of OAC in AF patients in a tertiary Hospital. We enrolled all patients with complete data of medical record. The data of the use of OAC in AF patients is taken from patients that was hospitalized in Cardiology ward during January 2015-August 2016. Patients were given OAC during hospitalization. Sixty three patients with atrial fibrillation were analysed in this study. Incidence of valvular disease was higher than non-valvular atrial fibrillation (65% vs 35% patients). Most of the patients was women (67.4%). Warfarin as oral anticoagulant for thromboembolic prevention was still more popular than dabigatran (61.8% vs 34.2%). Almost of patients had low HAS-BLED score. The intrahospital bleeding occured in 6% of all patients given warfarin. Warfarin is still used as a mainstay therapy in AF patients for thromboembolic prevention. Bleeding rate due to warfarin use for hospitalized patients was rare